# Phase II Study of QLC2519 in Pediatric Solid Tumor Participants

> **NCT07724756** · PHASE2 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Pediatric Malignant Solid Tumor
- Febrile Neutropenia (FN)
- Neutropenia

## Interventions

- **DRUG:** Albipagrastim alf

## Key facts

- **NCT ID:** NCT07724756
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-26
- **Primary completion:** 2027-06-26
- **Final completion:** 2028-06-26
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724756, "Phase II Study of QLC2519 in Pediatric Solid Tumor Participants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07724756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*